Literature DB >> 19535803

Autologous hematopoietic stem-cell transplantation for multiple myeloma.

Jean-Luc Harousseau1, Philippe Moreau.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19535803     DOI： 10.1056/NEJMct0805626

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  49 in total

1.  Reconstitution of regulatory T cells after autologous transplantation in multiple myeloma.

Authors:  Prasanth Ganeshan; Ritu Gupta; Mrinali Hakim; Lalit Kumar; Archana Bhaskar; Atul Sharma
Journal:  Int J Hematol       Date:  2011-11-03       Impact factor: 2.490

2.  IgM multiple myeloma: disease definition, prognosis, and differentiation from Waldenstrom's macroglobulinemia.

Authors:  Steven R Schuster; Sundararajan Vincent Rajkumar; Angela Dispenzieri; William Morice; Alvaro Moreno Aspitia; Stephen Ansell; Robert Kyle; Joseph Mikhael
Journal:  Am J Hematol       Date:  2010-11       Impact factor: 10.047

Review 3.  Treatment of autologous stem cell transplant-eligible multiple myeloma patients: ten questions and answers.

Authors:  Mohamad Mohty; Jean-Luc Harousseau
Journal:  Haematologica       Date:  2014-03       Impact factor: 9.941

4.  Comparison of 1-day vs 2-day dosing of high-dose melphalan followed by autologous hematopoietic cell transplantation in patients with multiple myeloma.

Authors:  S R Parmar; R Bookout; J F Shapiro; R Tombleson; J Perkins; J Kim; B Yue; M Tomblyn; M Alsina; T Nishihori
Journal:  Bone Marrow Transplant       Date:  2014-03-24       Impact factor: 5.483

5.  An Innovative, Comprehensive Mapping and Multiscale Analysis of Registered Trials for Stem Cell-Based Regenerative Medicine.

Authors:  Paul Monsarrat; Jean-Noel Vergnes; Valérie Planat-Bénard; Philippe Ravaud; Philippe Kémoun; Luc Sensebé; Louis Casteilla
Journal:  Stem Cells Transl Med       Date:  2016-04-13       Impact factor: 6.940

6.  Symptom experience of multiple myeloma (syMMex) patients treated with autologous stem cell transplantation following high-dose melphalan: a descriptive longitudinal study.

Authors:  Matthias Naegele; Monika Kirsch; Gabriele Ihorst; Katharina Fierz; Monika Engelhardt; Sabina De Geest
Journal:  Support Care Cancer       Date:  2017-09-16       Impact factor: 3.603

7.  Lower glomerular filtration rate predicts increased hepatic and mucosal toxicity in myeloma patients treated with high-dose melphalan.

Authors:  Masaharu Tamaki; Hideki Nakasone; Ayumi Gomyo; Jin Hayakawa; Yu Akahoshi; Naonori Harada; Machiko Kusuda; Yuko Ishihara; Koji Kawamura; Aki Tanihara; Miki Sato; Kiriko Terasako-Saito; Kazuaki Kameda; Hidenori Wada; Misato Kikuchi; Shun-Ichi Kimura; Shinichi Kako; Yoshinobu Kanda
Journal:  Int J Hematol       Date:  2018-07-23       Impact factor: 2.490

8.  Variability of high-dose melphalan exposure on oral mucositis in patients undergoing prophylactic low-level laser therapy.

Authors:  Gustavo Henrique Rodrigues; Graziella Chagas Jaguar; Fabio Abreu Alves; Andre Guollo; Vanessa Oliveira Camandoni; Aline Santos Damascena; Vladmir Claudio Cordeiro Lima
Journal:  Lasers Med Sci       Date:  2017-05-16       Impact factor: 3.161

9.  MTI-101 (cyclized HYD1) binds a CD44 containing complex and induces necrotic cell death in multiple myeloma.

Authors:  Anthony W Gebhard; Priyesh Jain; Rajesh R Nair; Michael F Emmons; Raul F Argilagos; John M Koomen; Mark L McLaughlin; Lori A Hazlehurst
Journal:  Mol Cancer Ther       Date:  2013-09-18       Impact factor: 6.261

10.  Undifferentiated spondyloarthritis following allogeneic stem cell transplantation.

Authors:  Vijay R Karia; Raquel Cuchacovich; Luis R Espinoza
Journal:  BMC Musculoskelet Disord       Date:  2010-06-25       Impact factor: 2.362
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.